JP2023521361A5 - - Google Patents
Info
- Publication number
- JP2023521361A5 JP2023521361A5 JP2022561426A JP2022561426A JP2023521361A5 JP 2023521361 A5 JP2023521361 A5 JP 2023521361A5 JP 2022561426 A JP2022561426 A JP 2022561426A JP 2022561426 A JP2022561426 A JP 2022561426A JP 2023521361 A5 JP2023521361 A5 JP 2023521361A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- seq
- cov
- affinity molecule
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20168929 | 2020-04-09 | ||
| EP20168929.6 | 2020-04-09 | ||
| EP20176023.8 | 2020-05-22 | ||
| EP20176023 | 2020-05-22 | ||
| EP20180781 | 2020-06-18 | ||
| EP20180781.5 | 2020-06-18 | ||
| EP20204036 | 2020-10-27 | ||
| EP20204036.6 | 2020-10-27 | ||
| PCT/EP2021/059328 WO2021205012A1 (en) | 2020-04-09 | 2021-04-09 | Aptamers for use in the treatment of coronaviridae infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521361A JP2023521361A (ja) | 2023-05-24 |
| JP2023521361A5 true JP2023521361A5 (enExample) | 2024-08-02 |
Family
ID=84191962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561426A Pending JP2023521361A (ja) | 2020-04-09 | 2021-04-09 | コロナウイルス科感染の治療において使用するためのアプタマー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606828B2 (enExample) |
| EP (1) | EP4133083A1 (enExample) |
| JP (1) | JP2023521361A (enExample) |
| KR (1) | KR20220166337A (enExample) |
| CN (1) | CN115768895A (enExample) |
| AU (1) | AU2021252151A1 (enExample) |
| BR (1) | BR112022020439A2 (enExample) |
| CA (1) | CA3175067A1 (enExample) |
| IL (1) | IL297155A (enExample) |
| MX (1) | MX2022012618A (enExample) |
| ZA (1) | ZA202212179B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3007984T3 (en) * | 2021-04-09 | 2025-03-21 | Berlin Cures GmbH | Aptamers for use in the treatment of coronaviridae infections |
| KR102937192B1 (ko) * | 2023-01-25 | 2026-03-17 | 주식회사 리젠시스랩 | 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도 |
| WO2025146959A1 (ko) * | 2024-01-02 | 2025-07-10 | 충북대학교 산학협력단 | ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508473A (ja) * | 2005-08-26 | 2009-03-05 | アーケミツクス・コーポレイシヨン | 高親和性でトロンビンに結合するアプタマー |
| EP2497828A1 (en) * | 2011-03-07 | 2012-09-12 | Charité - Universitätsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
| KR102596343B1 (ko) * | 2016-11-23 | 2023-10-31 | 베를린 큐어스 게엠베하 | TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer) |
-
2021
- 2021-04-09 KR KR1020227039288A patent/KR20220166337A/ko active Pending
- 2021-04-09 EP EP21716761.8A patent/EP4133083A1/en active Pending
- 2021-04-09 BR BR112022020439A patent/BR112022020439A2/pt unknown
- 2021-04-09 MX MX2022012618A patent/MX2022012618A/es unknown
- 2021-04-09 AU AU2021252151A patent/AU2021252151A1/en active Pending
- 2021-04-09 JP JP2022561426A patent/JP2023521361A/ja active Pending
- 2021-04-09 CN CN202180041090.7A patent/CN115768895A/zh active Pending
- 2021-04-09 CA CA3175067A patent/CA3175067A1/en active Pending
- 2021-04-09 US US17/995,705 patent/US12606828B2/en active Active
- 2021-10-14 IL IL297155A patent/IL297155A/en unknown
-
2022
- 2022-11-08 ZA ZA2022/12179A patent/ZA202212179B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mahmud et al. | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study | |
| Atlante et al. | The epigenetic implication in coronavirus infection and therapy | |
| US12006500B2 (en) | Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV) | |
| JP2006525796A5 (enExample) | ||
| Sauerhering et al. | Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-λ in vitro and in mice | |
| Kicmal et al. | Polyamine depletion abrogates enterovirus cellular attachment | |
| US20240102015A1 (en) | Antisense Oligonucleotides Targeting SARS-CoV-2 | |
| Kaina | On the origin of SARS-CoV-2: did cell culture experiments lead to increased virulence of the progenitor virus for humans? | |
| Lim et al. | Asunaprevir, a potent Hepatitis C virus protease inhibitor, blocks SARS-CoV-2 propagation | |
| Qiao et al. | The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition | |
| CN115844883A (zh) | 四溴苯三唑抑制猪流行性腹泻病毒体外感染的方法及应用 | |
| Tang et al. | Application of siRNA against SARS in the rhesus macaque model | |
| Pålsson et al. | Single-stranded oligonucleotide-mediated inhibition of respiratory syncytial virus infection | |
| Warrier et al. | Role of sindbis virus capsid protein region II in nucleocapsid core assembly and encapsidation of genomic RNA | |
| Leibowitz et al. | Genetic determinants of mouse hepatitis virus strain 1 pneumovirulence | |
| US20070203082A1 (en) | RNAI Agents For Anti-SARS Coronavirus Therapy | |
| Fukushima et al. | Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus | |
| Zeng et al. | Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future | |
| Lin et al. | Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus | |
| Junior | Interaction energies of the human ACE2 molecular recognition by SARS-CoV-2 | |
| Sarkar et al. | Potential Drug Strategies to Target Coronaviruses | |
| CN114246859A (zh) | 穿心莲内酯在制备用于治疗冠状病毒感染的产品中的应用 | |
| Getso et al. | Therapeutic strategies for COVID-19 patients: An update | |
| Shahin et al. | The selective effect of Ivermectin on different human coronaviruses; in-vitro study | |
| CN114246853B (zh) | 异阿魏酸在制备用于防治冠状病毒感染的产品中的应用 |